Most Read Articles
5 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
5 days ago
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

3 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.

Multidisciplinary therapy comparable to standard treatment for cutting cardiovascular markers in ACS

06 Dec 2019

Screening for obstructive sleep apnoea and multifaceted treatment during the subacute phase of acute coronary syndrome (ACS) does not lower cardiovascular marker levels more than standard therapy, a recent study has found.

Researchers randomly assigned 159 patients to receive either sleep-study guided multidisciplinary therapy (SGMT; n=70; mean age, 55.6±9.0 years; 91.4 percent male) or standard therapy (n=89; mean age, 54.2±7.4 years; 87.6 percent male). The primary study endpoint was the change in plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels after 7 months.

NT-proBNP decreased with time in both treatment arms. No significant between-group differences were reported at baseline (579±1,117 vs 611±899 pg/dL; p=0.851) and after 4 (115±222 vs 114±226 pg/dL; p=0.990) and 7 (90±167 vs 93±174 pg/dL; p=0.996) months of follow-up.

Similarly, the magnitudes of change from baseline were comparable between groups after 4 (–464 vs –497 pg/dL; p=0.792) and 7 (–489 vs –518 pg/dL; p=0.726) months.

Levels of plasma suppression of tumorigenicity 2 and high-sensitivity C-reactive protein likewise were not significantly different between the two groups.

These resulted in similar risks. At the 7-month follow-up, the estimated likelihood of developing fatal cardiovascular disease within 10 years was 2.1±1.8 percent in the SGMT group and 2.0±2.4 percent in the controls (p=0.176). At this time point, major adverse cardiac and cerebrovascular events also occurred with comparable frequencies between groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
5 days ago
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

3 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.